Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

UNC Journalism School Takes Hearst Prize for 8th Consecutive Year
The University of North Carolina Hussman School of Journalism and Media won the overall intercollegiate first place title at the Hearst Journalism Awards Program’s Intercollegiate...
Thu Jun 4, 2026

How To Spend A Weekend In Chapel Hill, According To A Local
Pulling into Chapel Hill, is special, so drive up slowly. As you cruise along the main drag, Franklin Street, you’ll approach the heart of the...
Tue Jun 2, 2026

Carolina astronomers capture images of the cosmos
The difficulties associated with obtaining these rare glimpses of the cosmos make the stories behind them all the more mesmerizing. The UNC College of Arts...
Mon Jun 1, 2026

Hometown Hero: UNC Scientist Nabarun Dasgupta
Nabarun Dasgupta is an epidemiologist who heads up UNC’s opioid data lab. They help people with substance use by giving them information about what substances...
Sun May 31, 2026